Healthcare

The healthcare landscape is evolving at a rapid pace, driven by groundbreaking advancements in AI, robotics, big data, and personalised medicine.

With growing industry challenges such as litigation risks and regulatory compliance, companies must now navigate balancing their IP strategy with regulatory and legal requirements.

At HGF, we are at the forefront of IP protection, empowering innovators to secure their breakthroughs and shape the future of healthcare with confidence. With our unmatched multidisciplinary approach, paired with extensive, award-winning experience in defending and challenging patents, your innovations can receive secure protection.

Find a specialist
Go to: Chemistry
Go to: MedTech

Latest updates

SPCs for Combination Products – Will CJEU need to look again?

Key takeaways National courts have diverged on the interpretation of the EU Court of Justice’s latest decisions on SPCs for combination products – in particular on whether data in the …

Read article
Event - 16th September 2026

Basel seminar - New developments in SPCs

VENUE – Der Teufelhof Basel, The Archaeological Cellar Join us on Wednesday 16th September 5:30 – 8:00 pm (CEST) for our seminar on the latest developments in Supplementary Protection Certificates …

Event details

Playing Loose – CJEU asked to decide on combination SPCs

In a new referral (C-262/26), the EU’s Court of Justice has been asked to decide whether a medicine which receives a marketing authorisation (MA) as a monotherapy, but labelled with …

Read article

Excipient or active ingredient? Look to the marketing authorisation…

In his recently issued (non-binding) Opinion in the Halozyme referral to the Court of Justice of the EU (C-456/24), the Advocate General has delivered a decisive “no” to the question …

Read article

Six Sectors. Six Golds. Financial Times: Europe’s Leading Patent Law Firms 2026

HGF has once again been recognised with ‘Gold’ rankings across all six sectors in the Financial Times Special Report – Europe’s Leading Patent Law Firms 2026. We are one of …

Read article

Pro = Active? CJEU asked to decide

In a new referral to the EU’s Court of Justice (C-794/25), the CJEU has been asked to rule on the question whether an approved pro-drug of a previously approved active …

Read article
HGF

Santen Revisited – CJEU asked to think again on “first authorisation” for SPCs

A new referral to the Court of Justice of the EU (C-15/26) will once again consider what is meant by the “first marketing authorisation” requirement of Article 3(d) of the …

Read article

Case Law for Non-Reproducible Products as Prior Art

Does a non-reproducible commercially available product form part of the state of the art for a European patent application? This question was answered as “yes” in G 1/23 by the …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our agrochemicals specialists.

Contact us